Zinnat(Zinadol)
Cefuroxime
Zinnat and Zinadol are different trade names for the same medicine.
Zinnat is an antibiotic used in adults and children. The medicine works by killing the bacteria that cause infections. It belongs to a group of medicines called cephalosporins.
Zinnat may also be used:
Your doctor may check what type of bacteria caused your infection and check if the bacteria are sensitive to Zinnat during treatment.
Severe skin reactions have occurred with cefuroxime, including:
Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS). If you notice any of the symptoms related to severe skin reactions described in section 4, you should seek medical advice immediately.
Before taking Zinnat, you should discuss this with your doctor or pharmacist.
Zinnat is not recommended for use in children under 3 months, as the safety and efficacy of the medicine in this age group are not known.
During treatment with Zinnat, you should be aware of the possibility of allergic reactions, fungal infections (e.g., thrush), and severe diarrhea (pseudomembranous colitis). This will reduce the risk of complications. See "Side effects to look out for" in section 4.
Zinnat may affect the results of blood tests for sugar and a blood test called the Coombs test. If you are going to have a blood test, you should:
tell the person taking the blood samplethat you are taking Zinnat.
You should tell your doctor or pharmacist about all the medicines you are taking now or have taken recently, and about any medicines you plan to take.
Zinnat may reduce the effectiveness of oral contraceptives. If you are taking oral contraceptives while taking Zinnat, you should also use mechanical methods of contraception(e.g., condoms). If you have any doubts, you should consult your doctor.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before taking this medicine.
Zinnat may cause dizzinessand other side effects that may impair your alertness.
You should not drive or operate machineryif you do not feel well.
You should consult your doctorto see if Zinnat is a suitable medicine for you to take.
This medicine should always be taken as directed by your doctor or pharmacist. If you are unsure, you should consult your doctor or pharmacist again.
Zinnat is available in the following strengths: 125 mg, 250 mg, 500 mg.
Zinnat should be taken after a meal. This will help increase the effectiveness of the treatment.
Zinnat tablets should be swallowed whole with water.
Tablets should not be chewed, crushed, or divided- this may reduce the effectiveness of the treatment.
The recommended dose of Zinnat is 250 mg to 500 mg twice a day, depending on the severity and type of infection.
The recommended dose of Zinnat is 10 mg/kg body weight (not more than 125 mg) to 15 mg/kg body weight (not more than 250 mg) twice a day, depending on:
Zinnat is not recommended for use in children under 3 months, as the safety and efficacy of the medicine in this age group are not known.
Depending on the disease and how the patient responds to treatment, the initial dose may be changed or more than one treatment cycle may be necessary.
If you have kidney problems, your doctor may change the dose of Zinnat.
If this applies to you, you should tell your doctor.
If you take more than the recommended dose of Zinnat, you may experience neurological disorders, in particular, an increased risk of seizures(epileptic fits).
You should contact your doctor or call an emergency immediately. If possible, you should show the packaging of Zinnat.
You should not take a double dose to make up for a missed dose. You should take the next dose at the usual time.
It is important not to shorten the prescribed treatment period with Zinnat. You should not stop treatment without your doctor's advice, even if you feel better. Shortening the recommended treatment period may lead to a recurrence of the disease.
If you have any further doubts about taking this medicine, you should consult your doctor or pharmacist.
Like all medicines, Zinnat can cause side effects, although not everybody gets them.
A small number of people taking Zinnat have reported an allergic reaction or a potentially severe skin reaction. The symptoms may be:
May occur in more than 1 in 10 patients:
Common side effects that may be seen in blood tests:
May occur in more than 1 in 100 patients:
Uncommon side effects that may be seen in blood tests:
Other side effects occur in a very small number of patients, but the exact frequency is unknown:
Side effects that may be seen in blood tests:
If you experience any side effects, including any side effects not listed in the leaflet, you should tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety, Ministry of Health
Al. Jerozolimskie 181C
02-222 Warsaw
tel.: +48 22 49 21 301
fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help provide more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not store above 30°C.
Do not use if the tablets are broken or damaged in any way.
Do not use this medicine after the expiry date (EXP) stated on the packaging. The expiry date refers to the last day of the month stated.
The batch number (Lot) is stated on the packaging.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of Zinnat is cefuroxime: each coated tablet contains 500 mg of cefuroxime (as cefuroxime axetil).
The other ingredients are: microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium (type A), hydrogenated vegetable oil, colloidal anhydrous silica, coating: hypromellose, propylene glycol, methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), Opaspray white M-1-7120J (containing, among others, titanium dioxide (E 171) and sodium benzoate (E 211)).
Zinnat, 500 mg, coated tablets are white, capsule-shaped, smooth on one side, and with the imprint "GX EG2" on the other. The tablets are packaged in aluminum/aluminum blisters, in a cardboard box. The pack contains 14 coated tablets.
For more detailed information, you should contact the marketing authorization holder or the parallel importer.
GlaxoSmithKline Monoprosopi A.E.B.E
Leof. Kifisias 266
152 32 Chalandri
Greece
Glaxo Wellcome Operations
Bernard Castle
United Kingdom
GlaxoSmithKline Manufacturing SpA
Verona
Italy
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
SHIRAZ PRODUCTIONS Sp. z o.o.
ul. Tymiankowa 24/28
95-054 Ksawerów
Marketing authorization number in Greece, the country of export: 41698/5-11-2009
coated tablets 500 mg
Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Romania, Slovakia, Slovenia, Spain, United Kingdom
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.